Genmab CEO hopes for verdict in Johnson & Johnson arbitration soon

Jan van de Winkel, CEO of Genmab, hopes for a fast decision in the arbitration dispute, which concerns Darzalex royalties, with Johnson & Johnson-owned Janssen.

Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab

Genmab hopes to soon see a verdict in the large and potentially costly arbitration dispute with partner Johnson & Johnson concerning the rights to the huge revenue inflows from cancer drug Darzalex.

The conflict between the two parties began in 2020 and caused Johnson & Johnson to subsequently reduce royalty payments to Genmab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs